Mangoceuticals raises $2.5 million through equity offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules
December 18, 2025 8:30 AM ESTDALLAS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the Company), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investors investor warrants. Aggregate gross proceeds to the Company... More
